US 11332746
Compounds and methods for reducing LRRK2 expression
granted A61KA61K31/7115A61K31/712
Quick answer
US patent 11332746 (Compounds and methods for reducing LRRK2 expression) held by Ionis Pharmaceuticals, Inc. expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Ionis Pharmaceuticals, Inc.
- Grant date
- Tue May 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 26
- CPC classes
- A61K, A61K31/7115, A61K31/712, A61K31/7125, A61K47/02